NCT03572036View on ClinicalTrials.gov

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

April 16, 2021

Study Completion Date

April 16, 2021

Conditions
Pulmonary HypertensionSickle Cell Disease
Trial Locations (1)

20892

National Heart, Lung and Blood Institute (NHLBI), Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03572036 - Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension | Biotech Hunter | Biotech Hunter